Bristol Deferred Long Term Liab from 2010 to 2025
| BMY Stock | USD 59.18 0.28 0.48% |
Deferred Long Term Liabilities | First Reported 2009-06-30 | Previous Quarter 751 M | Current Value 427 M | Quarterly Volatility 2 B |
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 2 B or Selling General Administrative of 8.8 B, as well as many indicators such as Price To Sales Ratio of 2.95, Dividend Yield of 0.0274 or PTB Ratio of 6.94. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
Bristol | Deferred Long Term Liab |
Latest Bristol Myers' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Bristol Myers Squibb over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Bristol Myers' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Bristol Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 2,206,666,518 | |
| Geometric Mean | 1,499,798,586 | |
| Coefficient Of Variation | 88.54 | |
| Mean Deviation | 1,531,583,147 | |
| Median | 2,166,000,000 | |
| Standard Deviation | 1,953,688,447 | |
| Sample Variance | 3816898.5T | |
| Range | 6B | |
| R-Value | 0.34 | |
| Mean Square Error | 3609504T | |
| R-Squared | 0.12 | |
| Significance | 0.19 | |
| Slope | 140,591,418 | |
| Total Sum of Squares | 57253478.2T |
Bristol Deferred Long Term Liab History
About Bristol Myers Financial Statements
Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 2.5 B | 2.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.